MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.
27 January 2022 A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.
28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.
27 January 2022 A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.
28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.
27 January 2022 A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.
